Feedback / Questions
rVIIa-FP (CSL689) - CSL Behring
CSL: Investor R&D Briefing
(CSL Behring)
-
Dec 3, 2016 -
"Phase I study confirms rVIIa-FP has measurable FVIIa levels up to 48 hrs"
P1 data
•
Hemophilia
http://www.csl.com.au/docs/645/950/RD%20Investor%20Briefing%202016.pdf
Dec 3, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious